Caroline A. Foley

Caroline A. Foley

Auto-generated profile, based on publicly available information

Caroline A. Foley

Kymera Therapeutics, Inc., Watertown, MA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2023 in ACS Chemical Biology
Verified
Journal Article
Closed access
FBFrances M. Bashore
Frances M. Bashore
CFCaroline A. Foley
Caroline A. Foley
HOHan Wee Ong
Han Wee Ong
JRJustin M. Rectenwald
Justin M. Rectenwald
RHRonan P. Hanley
Ronan P. Hanley
LJLindsey I. James
Lindsey I. James

16 February 2023 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
CSCathy J. Spangler
Cathy J. Spangler
ASAleksandra Skrajna
Aleksandra Skrajna
CFCaroline A. Foley
Caroline A. Foley
ANAnh Nguyen
Anh Nguyen
GBGabrielle R. Budziszewski
Gabrielle R. Budziszewski
RMRobert K. McGinty
Robert K. McGinty

2 October 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DSDevan J. Shell
Devan J. Shell
CFCaroline A. Foley
Caroline A. Foley
QWQinhong Wang
Qinhong Wang
CSChelsea M. Smith
Chelsea M. Smith
SGShiva K. R. Guduru
Shiva K. R. Guduru
Kenneth PearceKenneth Pearce
Kenneth Pearce

9 June 2025 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
BCBeatrice Chiew
Beatrice Chiew
MGMenachem J. Gunzburg
Menachem J. Gunzburg
CFCaroline A. Foley
Caroline A. Foley
HZHong Zeng
Hong Zeng
ADAiping Dong
Aiping Dong
LJLindsey I. James
Lindsey I. James

23 June 2026 in Nature Communications
Verified
Journal Article
Open access
XFXue Fei
Xue Fei
ARAnand Ramanathan
Anand Ramanathan
CDCaroline A. Daigle
Caroline A. Daigle
MFMelissa Ford
Melissa Ford
VCVeronica Campbell
Veronica Campbell
XZXiao Zhu
Xiao Zhu
Targeted protein degradation has emerged as a promising drug modality, with potential applications across many immuno-inflammatory diseases. KT-474 is an orally bioavailable interleukin-1 receptor-associated kinase 4 (IRAK4) heterobifunctional degrader evaluated in clinical trials for atopic dermatitis and hidradenitis suppurativa. Here we present structural, biophysical, and computational characterization of an IRAK4:KT-474:CRBN/DDB1 complex. Cryo-EM structure of the complex reveals a unique and non-native protein-protein interaction (PPI) surface mediated by a network of polar and apolar contacts, including key hydrophobic engagements mediated by CRBN Phe150. This complex exhibits negative cooperativity, arising from an interplay between weakly favorable PPI and conformational flexibility of the degrader. Moreover, the structure provides insight into the selective degradation profile of KT-474. Our results offer important insights into the mechanism of action of KT-474 and highlight the value of cryo-EM structures in the optimization of protein degraders.